Actis Capital
Funds dine out in China
While the region’s phenomenal growth story has mostly sidelined any discussion of distress, insiders see that changing
Actis exits Asia Books in Thailand
Actis Capital and Thailand Equity Fund (TEF) have jointly exited their 100% stake in Asia Books, a leading foreign-language books and magazine vendor in Thailand, to Bangkok-based Berli Jucker Public Company.
Aureos targets $200m fund for India, Sri Lanka, Bangladesh
Aureos Capital is targeting a year-end close for a $200 million fund that will invest in India, Sri Lanka and Bangladesh. Balaji Srinivas, managing partner at Aureos India Advisers, told Bloomberg that the Aureos India Fund II would deploy around 15%...
Apax nears Jyothy stake buy - report
Apax Partners is reportedly closing in on a 26% stake in Mumbai-based consumer goods firm Jyothy Laboratories, bringing to an end a battle between several private equity firms over the $150 million deal.
Actis considers Sterling exit
Actis, a London-headquartered emerging markets investor, is set to exit its 80% stake in Gujarat-based Sterling Add-Life Medical Institute, the Business Standard reported, citing sources close to the deal.
Apax to bid for Indian transaction processing firm – report
Apax Partners is considering the purchase of a majority stake in Computer Age Management Services (CAMS), India’s leading mutual fund registry and transaction processing firm, the Times of India reported, citing people familiar with the situation.
PE funds eye Jyothy stake sale
Mumbai-based consumer goods firm Jyothy Laboratories is reportedly looking to sells a minority stake in itself in an effort raise up to $200 million, and has approached private equity funds including Actis, Apax Partners, Carlyle and TPG about the deal.
A Capital launches first outbound RMB fund
Hong Kong-based PE firm A Capital has teamed with the Beijing Municipal Bureau of Financial Work to launch China’s first reminbi-denominated outbound private equity fund, with an RMB3 billion ($456 million) target.
Actis on exit trail in India
UK government-backed Actis has begun the divestment process for several of its Indian investees as part of its efforts to close its second, $325 million market-focused fund, LiveMint reported.
Actis, GIC in Indian power deal
Emerging markets private equity specialists Actis and the Government of Singapore Investment Corporation will each invest $77 million into Indian power developer GVK Energy, a subsidiary of Hyderabad-based GVK Power and Infrastructure.
Actis, GIC invest $77 million in GVK Energy
One month after Indian power giant GVK Energy received a $182 million investment from 3i India, Actis and SWF the Government of Singapore Investment Corporation (GIC) have also pledged $77 million in the company.
Actis set to invest $125 million in SuperMax - reports
The same week that London-headquartered Actis announced its exit from Paras Pharmaceuticals, reports have surfaced that the emerging markets investment firm is set to inject up to $125 million for a minority stake in SuperMax Corp., a maker of shaving...
Actis exits 63% stake in India's Paras for 10x return
Actis, the London-headquartered emerging markets investment firm, will sell its 63% stake in Paras Pharmaceuticals Limited to Benckiser Group, a UK-based company selling household, health and personal care products.
The great India debate
Private equity investment deals in India may be tricky, expensive and atypical compared to the standard private equity model, but they are potentially lucrative and poised to become even more attractive.
Actis announces new China, India partner promotions
Actis has announced the promotion of four of its directors to partner status, all of them in Asia: Tao Sun and Dong Zhong, based in Beijing; and Sanjiv Aggarwal and Shomik Mukherjee, both based in Mumbai.
DLA Piper engages Xu for Shanghai private equity/M&A work
DLA Piper has appointed Kaichen Xu to its Shanghai office as Of Counsel in its Corporate Group, to support the law firm's Greater China practice in private equity, VC and M&A work.
Actis's Benjamin Cheng resignation confirmed: update
Benjamin Cheng, Beijing-based partner with Actis, the leading UK emerging markets PE firm, has left the firm, a spokesperson at Actis’s London headquarters confirmed to AVCJ, following earlier reports.
Actis sells 30% stake in China's Inpac to Finland's Stora Enso
UK-based private equity firm Actis has agreed to sell its 30% stake in Inpac, a premier printed paper packaging (PPP) manufacturer in China, to Stora Enso, a global paper, packaging and wood products company headquartered in Finland.
Actis exits Sri Lanka's Ceylon Oxygen to Linde Group
Actis has exited its 95% stake in Sri Lankan industrial and medical gases business Ceylon Oxygen to global strategic peer The Linde Group, for an undisclosed amount.
India's GVK Power said still in talks with SCPEL, TPG
GVK Power and Infrastructure Ltd., an arm of Indian conglomerate GVK, is continuing talks with TPG Capital, Standard Chartered Private Equity Ltd. (SCPEL) and Morgan Stanley's infrastructure fund to invest some $250-300 million for up to 30% of its Mumbai...
Actis said seeking exit from India's Halonix
Actis is seeking a buyer for some or all of its 66% controlling stake in Indian halogen bulb and lamp manufacturer Halonix, in a deal which could fetch up to $56 million with a probable strategic buyer, according to Indian reports.
3i plans RMB fund under Queen's blueprint
UK private equity major 3i Group is planning to launch a renminbi-denominated fund as part of an overall two-year plan, announced 3i CEO Michael Queen, coming alongside the second Indian infrastructure fund expected since March this year.
Taisho, others assessing Actis, Sequoia India investee Paras Pharma
Japanese pharma major Taisho Pharmaceutical Co. Ltd., as well as at least one other leading non-Indian drug firm, is conducting due diligence on Actis Capital and Sequoia Capital investee Paras Pharmaceuticals, in a competitive exit process that could...
China private equity shooting for world No.1?
PRC to surpass US PE market size – or will it?